Lysozyme, when intended for application to the skin. (S4)
Malathion, except when intended and registered as an ectoparasiticide in terms of the provisions of the
Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Manganese salts, preparations thereof for injection, when intended for veterinary use.
Mebendazole, except intended and registered as an anthelmintic in terms of the provisions of the
Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Methenamine (hexamine), except when intended for application to the skin and except when intended
and registered as an urinary tract antiseptic in terms of the provisions of the Fertilizers, Farm Feeds,
Agricultural Remedies and Stock Remedies Act, 1947.
Methionine, when intended for medicinal purposes.
Miconazole when intended for application to the skin and when intended for human vaginal use,
specifically for the treatment of recurrent vaginal candidiasis. (S2, S4)
Microfibrillar collagen hydrochloride.
Morantel citrate, except when intended and registered as an anthelmintic in terms of the provisions of
the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
N-acetyl-aspartyl-glutamic acid.
Naphazoline, when intended for nasal use.
Naproxen, when intended for application to the skin (S2, S3)
Nicotine; when used as nicotine transdermal patches for continuous application to the skin in strengths
up to and including 15mg/16 hours when these medicines are used for the relief of nicotine withdrawal
symptoms as an aid to smoking cessation only. (S2), except nicotine gum containing 4mg or less
nicotine per piece where the pack size does not exceed 30 pieces per pack when these medicines are
used for the relief of nicotine withdrawal symptoms as an aid to smoking cessation only (S0).
Nitrofurantoin, when intended for application to the skin. (S4)
Nitrofurazone, when intended for application to the skin. (S4)
Nystatin, when intended for application to the skin and when intended for human vaginal use,
specifically for the treatment of recurrent vaginal candidiasis. (S4)
Omidazole, when intended for application to the skin. (S4)
Orthodichlorobenzene, when intended for topical human medicinal use.
Oxibendazole, except when intended and registered as an anthelmintic in terms of the provisions of the
Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Oxymetazoline, when intended for nasal use.
Paracetamol—
(1)
substances, preparations and mixtures, except—
(a)
in tablets or capsules each containing 500 milligrams or less of paracetamol, when—
(i)
packed in a primary pack containing not more than an aggregate of 12,5 grams of
paracetamol in such tablets or capsules;
(ii)
packed in blister strip packaging or in containers with child-resistant closures;
(iii)
the primary pack is labeled with the following boxed warning, placed prominently on at
least the main panel of the immediate container label and outer label (carton):
CONTAINS PARACETAMOL – READ THE PACKAGE INSERT;
(b)
in individually wrapped powders or in sachets containing 1 000 milligrams or less of
paracetamol, when—
(i)
packed in a primary pack containing not more than an aggregate of 12,5 grams of
paracetamol in such powders or sachets;
(ii)
the primary pack is labelled with the following boxed warning, placed prominently on
at least the main panel of the immediate container label and outer label (carton):
CONTAINS PARACETAMOL – READ THE PACKAGE INSERT;
(c)
in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5
millilitres or in paediatric dosage form (drops) containing 120 milligrams or less of paracetamol per 1,2
millilitres, when—
(i)
packed in a primary pack containing not more than 100 millilitres in the case of the
liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres;
(ii)
packed in a primary pack containing not more than 20 millilitres in the case of the
paediatric dosage form (drops) containing 120 milligrams or less of paracetamol per 1,2 millilitres;
(iii)
the primary pack is labelled with the following boxed warning, placed prominently on
at least the main panel of the immediate container label and outer label (carton):
CONTAINS PARACETAMOL – READ THE PACKAGE INSERT;
(2)
when contained in rectal suppositories. (S2)
Paradichlorobenzene, when intended for topical human medicinal use.
Penciclovir, when intended for application to the lips in the early treatment of recurrent Herpes simplex
virus infections. (S4)
Pentosan polysulfate sodium, except when intended for the treatment of interstitial cystitis. (S3)
Phenylephrine, except ophthalmic preparations containing 0,2 per cent or less of phenylephrine.
Phospholipids, when applied for therapeutic purposes.
Procaine hydrochloride, when intended for oral administration.